Core Viewpoint - The article discusses the recent exposure of a chain pharmacy, Dacianlin, for selling ordinary consumer products disguised as medical devices, allowing them to be reimbursed by health insurance, raising concerns about compliance and regulatory scrutiny in the industry [2][6]. Group 1: Company Overview - Dacianlin operates a large chain of pharmacies, with over 17,000 stores as of September 2023, making it the largest pharmacy chain in terms of store count in China [6]. - The company reported non-pharmaceutical revenue of 2.948 billion yuan in 2024, with a gross margin of 42%, which is 9 percentage points higher than its average gross margin of 32.74% [6]. - Dacianlin's sales contract with the manufacturer of the disputed products amounts to nearly 900 million yuan [6]. Group 2: Regulatory Issues - The company has faced multiple instances of non-compliance with health insurance fund usage, with violations including improper billing practices and inclusion of non-reimbursable items in insurance claims [7][8]. - Dacianlin has implemented a "direct management franchise" model to strengthen control over franchise stores, requiring all products to be sourced from the company [8]. - Despite these measures, violations have continued, leading to penalties and fines for various stores [8]. Group 3: Market Context - The practice of misclassifying consumer goods as medical devices to benefit from insurance reimbursement has become common in the industry, with several other major pharmacy chains also implicated [6]. - The tightening of health insurance regulations is expected to increase scrutiny on such practices, potentially impacting the business model of companies like Dacianlin [6]. Group 4: Information Disclosure and Corporate Governance - Dacianlin's information disclosure rating improved to B grade from D grade, reflecting past issues with timely disclosures related to legal matters involving its actual controller [9]. - The company faced regulatory actions for failing to disclose critical information promptly, leading to penalties and a requirement for internal accountability measures [10].

封面来源：大参林门店 【编者按：ESG年报解读是搜狐财经及价值公司100联合发起的针对各公司ESG报告披露情况的解读专栏。参考上交所《上市公司治理准则》、港交所《环 境、社会及管治守则》等文件，迭代完善各行业ESG星级测评体系标准，并以最新标准为依托，以2024年公司ESG报告为主要数据来源，对公司2024年环境 资源、社会责任及公司管治进行评价】 ——本文为"大参林"篇。 套刷医保 近日，一则日用品穿上医疗器械"马甲"变身医保"购物卡"的新闻，经央视曝光后，登上热搜榜单。报道显示，某连锁药房销售的所谓"医用隔离垫"，实际上 只是普通的防晒冰袖和防晒口罩，却能通过医保结算。 图：央视 调查视频 上述产品的生产厂商超亚新材料公司称，这些产品已取得第一类医疗器械备案凭证及医保编码，生产、包装与供货流程均符合规定。根据国家市场监管总局 2021年10月起实施的《医疗器械注册与备案管理办法》，第一类医疗器械实行备案管理，企业无需开展临床试验，向市级药监部门备案后即可生产销售。 上述产品通过正规渠道进入大参林等连锁药店销售，其中超亚公司与大参林药店的合同销售金额接近9000万元。而视频中出现的大参林药店，主要从事中西 ...

Core Viewpoint - Recent reports indicate that consumers are being encouraged to misuse their medical insurance cards for purchasing non-medical items, raising concerns about the integrity of the healthcare system and potential regulatory implications [1] Group 1: Consumer Behavior - Consumers are being taught through online platforms how to exploit their medical insurance cards to buy everyday items like dental floss, toothbrushes, facial towels, and skincare products, detaching these purchases from legitimate medical contexts [1] - The trend highlights a growing misuse of medical insurance benefits, as individuals treat their insurance funds as disposable income [1] Group 2: Industry Response - Major pharmacy chains such as Haiwangxingchen, Dacilin (603233), Zhang Zhongjing Pharmacy, and Foci Pharmacy are reportedly selling everyday products packaged as medical devices, promoting them with the ability to be purchased using medical insurance [1] - In specific instances, products not covered by insurance, such as cosmetic contact lenses, are also being sold under the guise of medical necessity, further complicating the issue [1]

Core Viewpoint - The A-share chain pharmacy industry is experiencing a significant adjustment period, characterized by high goodwill levels due to previous aggressive expansion strategies through mergers and acquisitions. Companies are now facing challenges in balancing scale effects with operational quality [1][2]. Goodwill Accumulation - As of the end of Q3, the total goodwill of six A-share chain pharmacy companies reached 20.778 billion yuan, with an average of 3.463 billion yuan per company. The highest goodwill was recorded by Lao Bai Xing at 5.763 billion yuan, followed by Yi Feng Pharmacy at 4.772 billion yuan and Da San Lin at 3.522 billion yuan [2]. - Goodwill as a percentage of current assets is notably high, with Lao Bai Xing at 65.28% and Jian Zhi Jia exceeding 50% at 58.7%. This trend of high goodwill has persisted for several years, with Lao Bai Xing's goodwill exceeding 5 billion yuan in 2022 [2]. Performance Trends - The performance of A-share chain pharmacies has shown divergence in the first three quarters of this year. While Shuyu Pingmin has reported a revenue increase of 5.19% to 7.446 billion yuan and turned a profit of 109 million yuan, other companies like Lao Bai Xing have seen declines in net profit by 16.11% to 529 million yuan [4]. - Despite the overall decline in net profit for some companies, Lao Bai Xing showed signs of recovery in Q3 with a slight revenue increase of 0.07% [4]. Store Count Decline - Many chain pharmacy companies are experiencing a decline in the number of stores. Lao Bai Xing reported a net decrease of 240 direct stores this year, while Yi Feng Pharmacy closed 440 stores and opened only 137 [7]. - Jian Zhi Jia also closed more stores than it opened, with a net decrease of 38 stores. In contrast, Shuyu Pingmin increased its direct store count due to acquisitions, reflecting a shift in focus from quantity to quality in store management [7]. Industry Direction - As market saturation increases, the strategy of merely expanding store numbers is becoming less effective. The future direction for chain pharmacies should focus on high-quality service and enhancing customer experience to improve competitiveness [8].

Core Viewpoint - The A-share chain pharmacy industry is experiencing a significant adjustment period, marked by high goodwill levels due to previous aggressive expansion strategies through mergers and acquisitions. Companies are now facing declining store numbers and must balance scale effects with operational quality [2][5]. Goodwill Accumulation - As of the end of Q3, the total goodwill of six A-share chain pharmacy companies reached 20.778 billion yuan, with an average of 3.463 billion yuan per company [4]. - The company "老百姓" holds the highest goodwill at 5.763 billion yuan, followed by "益丰药房" at 4.772 billion yuan and "XD大参林" at 3.522 billion yuan [4][5]. - Goodwill as a percentage of current assets is notably high for "老百姓" at 65.28% and "健之佳" at 58.7%, indicating a heavy reliance on acquired goodwill [4]. Performance Trends - The performance of A-share chain pharmacies has shown divergence in the first three quarters of the year, with "漱玉平民" recovering from previous losses, achieving a revenue of 7.446 billion yuan, a year-on-year increase of 5.19% [7]. - "老百姓" reported a revenue decline of 1% to 16.07 billion yuan and a net profit drop of 16.11% to 529 million yuan [8]. - Other companies like "大参林" and "益丰药房" have also seen net profit growth, while "健之佳" and "一心堂" experienced declines [7][8]. Store Count Changes - Many chain pharmacy companies are witnessing a decline in store numbers, with "老百姓" reducing its direct stores by 240 this year [10]. - "益丰药房" closed 440 stores while opening only 137, resulting in a slight overall decrease in store count [10]. - In contrast, "漱玉平民" increased its direct store count due to new acquisitions, indicating a shift towards quality over quantity in store management [11]. Industry Direction - The industry is transitioning from a focus on expanding store numbers to enhancing service quality and operational efficiency, as market saturation makes previous growth strategies less effective [11].

Core Viewpoint - The A-share chain pharmacy industry is experiencing a significant adjustment period, marked by high goodwill levels and a decline in the number of direct-operated stores, necessitating a balance between scale effects and operational quality [1][4]. Goodwill Accumulation - As of the end of Q3, the total goodwill of six A-share chain pharmacy companies reached 20.778 billion yuan, with the highest being 5.763 billion yuan for Lao Bai Xing [1][3]. - Goodwill accounts for over 50% of current assets for Lao Bai Xing and Jian Zhi Jia, indicating a heavy reliance on past acquisitions for growth [1][3]. Performance Trends - The performance of the six major A-share chain pharmacies has shown divergence in the first three quarters of the year, with some companies like Shu Yu Ping Min recovering from previous losses, achieving a revenue of 7.446 billion yuan, a year-on-year increase of 5.19% [5][6]. - Lao Bai Xing reported a revenue decline of 1% to 16.07 billion yuan and a net profit drop of 16.11% to 529 million yuan in the same period, although it showed signs of recovery in Q3 [6][8]. Store Count Changes - Many chain pharmacy companies have seen a decrease in the number of stores, with Lao Bai Xing reducing its direct-operated stores by 240 to 9,981 by the end of Q3 [8][9]. - Yi Feng Pharmacy and Jian Zhi Jia also reported net decreases in store counts, reflecting a shift from quantity to quality in store management [8][9]. Industry Outlook - The industry is transitioning from a focus on rapid expansion through store count to enhancing service quality and operational efficiency, as market saturation makes previous growth strategies less effective [9].

Group 1: 华勤技术 (603296.SH) - The company achieved a revenue of 128.82 billion yuan in the first three quarters of 2025, representing a year-on-year increase of 70% [7] - The net profit attributable to shareholders reached 3.099 billion yuan, up 51% year-on-year [7] - The company’s gross margin improved to 8.17% in Q3 2025, an increase of 1.04 percentage points from Q2 2025 [7] - The company is expanding its global manufacturing layout, achieving large-scale shipments in India and Vietnam [8] - The multi-category business strategy is expected to drive significant performance growth, with projected net profits of 4.15 billion yuan, 5.15 billion yuan, and 6.17 billion yuan from 2025 to 2027 [8] Group 2: 汉朔科技 (301275.SZ) - The company reported a revenue of 2.809 billion yuan in the first three quarters of 2025, a decrease of 11% year-on-year [10] - The net profit attributable to shareholders was 314 million yuan, down 41% year-on-year [10] - The gross margin for Q3 2025 was 35.94%, an increase of 5.23 percentage points from Q2 2025, indicating a recovery in profitability [10] - The company is focusing on digitalization in the retail sector, with a business model centered around electronic price tag systems and SaaS cloud platform services [11] - Projected revenues for 2025 to 2027 are 4.056 billion yuan, 4.787 billion yuan, and 5.747 billion yuan, respectively [11] Group 3: 天山电子 (301379.SZ) - The company achieved a revenue of 1.338 billion yuan in the first three quarters of 2025, a year-on-year increase of 26.48% [12] - The net profit attributable to shareholders was 113 million yuan, up 7.75% year-on-year [12] - The company is strategically investing in the storage sector, aiming to create a complete storage ecosystem [13] - The projected revenues for 2025 to 2027 are 1.978 billion yuan, 2.546 billion yuan, and 2.893 billion yuan, respectively [13] Group 4: 恒瑞医药 (600276.SH) - The company reported a revenue of 23.188 billion yuan in the first three quarters of 2025, representing a 14.85% increase [15] - The net profit attributable to shareholders was 5.751 billion yuan, up 24.50% year-on-year [15] - The company is accelerating its internationalization efforts, with multiple overseas collaborations and licensing agreements [16] - The projected net profits for 2025 to 2027 are 8.8 billion yuan, 10.28 billion yuan, and 12.15 billion yuan, respectively [18] Group 5: 益丰药房 (603939.SH) - The company achieved a revenue of 17.286 billion yuan in the first three quarters of 2025, a slight increase of 0.39% [20] - The net profit attributable to shareholders was 1.225 billion yuan, up 10.27% year-on-year [20] - The company is focusing on non-pharmaceutical innovations, which are expected to drive growth in the future [21] - The company plans to optimize its store network and expand its franchise business, with a total of 14,666 stores as of Q3 2025 [21] Group 6: 中兴通讯 (000063.SZ) - The company reported a revenue of 100.52 billion yuan in the first three quarters of 2025, a year-on-year increase of 11.63% [23] - The net profit attributable to shareholders was 5.32 billion yuan, down 32.7% year-on-year [23] - The company is experiencing pressure in its operator business, but its computing power segment is showing significant growth [24] - The projected net profits for 2025 to 2027 are 7.4 billion yuan, 8.5 billion yuan, and 10 billion yuan, respectively [24] Group 7: 德科立 (688205.SH) - The company achieved a revenue of 6.5 billion yuan in the first three quarters of 2025, a year-on-year increase of 8.6% [26] - The net profit attributable to shareholders was 40 million yuan, down 47.4% year-on-year [26] - The company is focusing on DCI (Data Center Interconnect) products, which are experiencing accelerated growth [27] - The projected net profits for 2025 to 2027 are 70 million yuan, 250 million yuan, and 410 million yuan, respectively [27] Group 8: 北新建材 (000786.SZ) - The company reported a revenue of 19.905 billion yuan in the first three quarters of 2025, a decrease of 2.25% year-on-year [29] - The net profit attributable to shareholders was 2.586 billion yuan, down 17.77% year-on-year [29] - The company is facing challenges in its gypsum board business but is seeing growth in its other segments [30] - The projected net profits for 2025 to 2027 are 3.364 billion yuan, 3.959 billion yuan, and 4.432 billion yuan, respectively [32]

Group 1 - The company announced a cash dividend distribution of 0.14 yuan per share (including tax), totaling 106 million yuan (including tax) based on a total share capital of 759 million shares prior to the distribution [1] - The record date for the dividend distribution is set for November 11, 2025, and the ex-dividend date is November 12, 2025 [1]

Group 1: China Jushi (600176.SH) - The company achieved a revenue of 139.04 billion yuan in the first three quarters of 2025, representing a year-on-year increase of 19.53% [6] - The net profit attributable to shareholders reached 25.68 billion yuan, up 67.51% year-on-year, with a non-recurring net profit of 26.12 billion yuan, increasing by 125.91% [6][9] - The company is expected to achieve net profits of 34.91 billion, 41.07 billion, and 46.48 billion yuan from 2025 to 2027, driven by the recovery of fiberglass prices and demand from various downstream sectors [9] Group 2: Transsion Holdings (688036.SH) - The company reported a revenue of 204.66 billion yuan in Q3 2025, a year-on-year increase of 22.60%, while the net profit attributable to shareholders was 9.35 billion yuan, down 11.06% year-on-year [11] - The company is expected to achieve revenues of 694.0 billion, 751.7 billion, and 871.6 billion yuan from 2025 to 2027, with net profits of 38.2 billion, 56.7 billion, and 70.8 billion yuan respectively [13] Group 3: Tonglian Precision (688210.SH) - The company reported a revenue of 2.4 billion yuan in Q3 2025, a year-on-year increase of 5.75%, while the net profit attributable to shareholders was 884,000 yuan, down 91.67% year-on-year [15] - The company is expected to achieve revenues of 11.4 billion, 15.5 billion, and 21.1 billion yuan from 2025 to 2027, with net profits of 1.0 billion, 1.9 billion, and 2.9 billion yuan respectively [17] Group 4: Topband Co., Ltd. (002139.SZ) - The company achieved a revenue of 26.9 billion yuan in Q3 2025, a slight increase of 0.1% year-on-year, while the net profit attributable to shareholders was 900 million yuan, down 44.7% year-on-year [18] - The company is expected to achieve net profits of 6.2 billion, 8.5 billion, and 10.8 billion yuan from 2025 to 2027 [19] Group 5: Inspur Information (000977.SZ) - The company reported a revenue of 1206.69 billion yuan in the first three quarters of 2025, a year-on-year increase of 45%, with a net profit of 14.82 billion yuan, up 15% year-on-year [25] - The company is expected to achieve net profits of 26.38 billion, 37.31 billion, and 47.77 billion yuan from 2025 to 2027 [26] Group 6: Benda Pharmaceutical (300558.SZ) - The company achieved a revenue of 27.17 billion yuan in the first three quarters of 2025, a year-on-year increase of 15.90%, while the net profit attributable to shareholders was 3.17 billion yuan, down 23.86% year-on-year [28] - The company is expected to achieve revenues of 35.50 billion, 43.71 billion, and 53.09 billion yuan from 2025 to 2027, with net profits of 5.73 billion, 7.21 billion, and 8.56 billion yuan respectively [29] Group 7: XWANDA (300207.SZ) - The company reported a revenue of 435.34 billion yuan in the first three quarters of 2025, a year-on-year increase of 13.73%, with a net profit of 14.05 billion yuan, up 15.94% year-on-year [35] - The company is expected to achieve net profits of 21.83 billion, 30.29 billion, and 40.31 billion yuan from 2025 to 2027 [37] Group 8: YH Technology (688080.SH) - The company achieved a revenue of 2 billion yuan in Q3 2025, a year-on-year increase of 34.5%, with a net profit of 400 million yuan, up 17.5% year-on-year [39] - The company is expected to achieve net profits of 1.5 billion, 2 billion, and 2.6 billion yuan from 2025 to 2027 [40] Group 9: Zhongji Xuchuang (300308.SZ) - The company reported a revenue of 102.2 billion yuan in Q3 2025, a year-on-year increase of 56.8%, with a net profit of 31.4 billion yuan, up 125% year-on-year [42] - The company is expected to achieve net profits of 107 billion, 205 billion, and 268 billion yuan from 2025 to 2027 [43] Group 10: Dongfang Tower (002545.SZ) - The company achieved a revenue of 33.92 billion yuan in the first three quarters of 2025, a year-on-year increase of 9.05%, with a net profit of 8.28 billion yuan, up 77.57% year-on-year [44] - The company is expected to achieve net profits of 12.68 billion, 14.46 billion, and 17.19 billion yuan from 2025 to 2027 [46]

Investment Rating - The investment rating for the company is "Buy" [5][3]. Core Insights - The company reported a revenue of 20.068 billion yuan for Q1-Q3 2025, representing a year-on-year increase of 1.71%, while the net profit attributable to shareholders was 1.081 billion yuan, up 25.97% year-on-year [1][5]. - The company has entered a phase of optimizing store layouts and focusing on direct franchise stores, with a total of 17,385 stores as of Q3 2025, including 7,029 franchise stores [2]. - The retail business gross margin increased to 37.70%, and the sales expense ratio improved to 21.78% [2]. Financial Performance Summary - For Q1-Q3 2025, the company achieved a revenue of 20.068 billion yuan, with a net profit of 1.081 billion yuan, and a net profit excluding non-recurring items of 1.073 billion yuan [1][5]. - The revenue from traditional Chinese and Western medicine was 15.451 billion yuan, with a gross margin of 30.12% [1]. - The company expects EPS of 1.06, 1.21, and 1.41 yuan for 2025, 2026, and 2027 respectively [3]. Store Expansion and Management - The company completed its cross-province expansion and is now focusing on increasing market share in existing provinces, with a net increase of 832 stores in Q1-Q3 2025 [2]. - The company has optimized its store network by closing 447 stores while opening 300 new self-built stores and adding 979 franchise stores [2]. Profitability and Efficiency - The company is benefiting from improved gross margins in non-pharmaceutical products, which increased to 45.62% [1]. - The digital transformation has enhanced operational efficiency, contributing to a competitive advantage [2]. Future Earnings Projections - The company is projected to have a revenue of 27.186 billion yuan in 2025, with a growth rate of 2.6% [4]. - The net profit attributable to shareholders is expected to reach 1.205 billion yuan in 2025, reflecting a growth rate of 31.7% [4].